uSINE-PAMS Artificial Intelligence Driven, Ultrasound-Guided Lumbar Puncture to Improve Procedural Accuracy
Launched by NATIONAL NEUROSCIENCE INSTITUTE · Apr 20, 2023
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new technology called uSINE-PAMS, which uses artificial intelligence to help doctors perform lumbar punctures more accurately. A lumbar puncture is a procedure where a needle is inserted into the lower back to collect fluid for testing or to administer medication. The trial aims to see if uSINE-PAMS can improve the success of this procedure compared to the traditional method, which relies on the doctor's experience and landmarks on the body.
To participate in this trial, you need to be at least 21 years old and scheduled for a lumbar puncture as part of your medical care. You should be able to give your consent for the procedure. However, there are some conditions that might exclude you, such as allergies to ultrasound gel, certain previous surgeries on your spine, or specific medical issues like infections or bleeding disorders. If you join the study, you can expect to have your lumbar puncture performed with the guidance of this new technology, which aims to make the procedure safer and more effective.
Gender
ALL
Eligibility criteria
- INCLUSION CRITERIA:
- • Patients planned for lumbar puncture as part of their clinical care
- • 21 years of age or older
- • Able to provide informed consent
- EXCLUSION CRITERIA:
- • Allergy to ultrasound gel
- • Previous lumbar spinal instrumentation
- • Patients with suspected spinal epidural abscess or any other infection at the potential site of needle entry on the back
- • Possible raised intracranial pressure with risk of cerebral herniation, including presence of obstructive hydrocephalus, intracranial space-occupying lesion and cerebral edema
- • Presence of significant thrombocytopenia (platelet \<40k) or other bleeding diathesis; patients on antiplatelet and/or anticoagulation may be included if their antiplatelet and/or anticoagulation can be and are stopped for an adequate duration prior to lumbar puncture according to the institution guidelines.
About National Neuroscience Institute
The National Neuroscience Institute (NNI) is a leading research organization dedicated to advancing the understanding and treatment of neurological disorders. With a focus on innovative clinical trials, NNI aims to develop cutting-edge therapies that improve patient outcomes and enhance the quality of life for individuals affected by a range of neurological conditions. The institute is committed to fostering collaboration among researchers, clinicians, and industry partners to translate scientific discoveries into practical solutions. Through rigorous research methodologies and a patient-centered approach, NNI strives to be at the forefront of neuroscience, driving progress in the field and contributing to global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported